CTOs on the Move

Axm Pharma

www.axmpharma.com

 
AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.axmpharma.com
  • 7251 W Lake Mead Blvd Ste 300
    Las Vegas, NV USA 89128
  • Phone: 702.562.4155

Executives

Name Title Contact Details

Similar Companies

Medical Center Compounding

Medical Center Compounding is a Cleveland, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ATLANTA WOMENS SPECIALIST PC

ATLANTA WOMENS SPECIALIST PC is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

Premier Research

Premier Research is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neotropix

Neotropix is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.